Please use this identifier to cite or link to this item:
|Title:||Community-based intervention to improve cardiometabolic targets in patients with stroke: a randomized controlled trial.|
|Epworth Authors:||Gerraty, Richard|
|Other Authors:||Olaiya, Muideen|
Transient Ischemic Attack
American Heart Association
Neurosciences Clinical Institute, Epworth HealthCare, Victoria, Australia
Department of Medicine, Epworth Healthcare, Australia.
|Publisher:||Lippincott Williams & Wilkins for American Heart Association|
|Citation:||Stroke. 2017 Sep;48(9):2504-2510|
|Abstract:||BACKGROUND AND PURPOSE: Many guidelines for secondary prevention of stroke focus on controlling cardiometabolic risk factors. We investigated the effectiveness of a management program for attaining cardiometabolic targets in survivors of stroke/transient ischemic attack. METHODS: Randomized controlled trial of survivors of stroke/transient ischemic attack aged ≥18 years. General practices were randomized to usual care (control) or an intervention comprising specialist review of care plans and nurse education in addition to usual care. The outcome is attainment of pre-defined cardiometabolic targets based on Australian guidelines. Multivariable regression was undertaken to determine efficacy and identify factors associated with attaining targets. RESULTS: Overall, 283 subjects were randomized to the intervention and 280 to controls. Although we found no between-group difference in overall cardiometabolic targets achieved at 12 months, the intervention group more often achieved control of low-density lipoprotein cholesterol (odds ratio, 1.97; 95% confidence interval, 1.18-3.29) than controls. At 24 months, no between-group differences were observed. Medication adherence was ≥80% at follow-up, but uptake of lifestyle/behavioral habits was poor. Older age, being male, being married/living with partner, and having greater functional ability or a history of diabetes mellitus were associated with attaining targets. CONCLUSIONS: The intervention in this largely negative trial only had a detectable effect on attaining target for lipids but not for other factors at 12 months or any factor at 24 months. This limited effect may be attributable to inadequate uptake of behavioral/lifestyle interventions, highlighting the need for new or better approaches to achieve meaningful behavioral change.|
|Affiliated Organisations:||Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences, Monash Health|
Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia.
Menzies Institute for Medical Research, Hobart, Tasmania, Australia.
Department of Neurosciences, Box Hill Hospital, Victoria, Australia.
Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
|Type of Clinical Study or Trial:||Randomized Controlled Clinical Trial|
|Appears in Collections:||Neurosciences|
Files in This Item:
There are no files associated with this item.
Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.